Update from Genzyme on Acid Sphingomyelinase Deficiency (ASMD) Development Efforts Adult Trial ~ January 28th, 2015
Dear NNPDF Families and Friends,
The NNPDF is pleased to provide you with the following update from Genzyme, a Sanofi Company, on NEWLY released information about the adult Phase 2 / 3 clinical trial of recombinant human acid sphingomyelinase (rhASM).
Please be advised of the following details associated with the adult Phase 2 / 3 clinical trial #: NCT02004691:
- The study is NOT yet open for patient recruitment
- Inclusion / Exclusion criteria are provided in the post
- Estimated enrollment of 35 adult patients
- MUST be 18 years and older
- The number of country clinical sites and locations has NOT yet been determined ~ but there will be clinic sites in multiple countries.